{
  "trial_id": "NCT01307579",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, creatinine clearance, serum creatinine, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), diagnosis type (e.g., newly diagnosed de novo AML, first or subsequent relapse of AML, secondary AML), history of prolonged antifungal therapy, pregnancy status, use of birth control method, lactation status.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Male",
          "gender"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "diagnosis type (e.g., newly diagnosed de novo AML, first or subsequent relapse of AML, secondary AML)"
        ],
        [
          "Race (NIH/OMB)",
          "diagnosis type (e.g., newly diagnosed de novo AML, first or subsequent relapse of AML, secondary AML)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "creatinine clearance",
        "serum creatinine",
        "total bilirubin",
        "aspartate aminotransferase (AST)",
        "alanine aminotransferase (ALT)",
        "history of prolonged antifungal therapy",
        "pregnancy status",
        "use of birth control method",
        "lactation status."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Type of AML, Creatinine clearance, Total bilirubin, AST, ALT, History of prolonged antifungal therapy,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Type of AML",
        "Creatinine clearance",
        "Total bilirubin",
        "AST",
        "ALT",
        "History of prolonged antifungal therapy"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, Acute Myeloid Leukemia (AML) diagnosis, Relapsed or refractory AML, Secondary AML, Myelodysplastic syndrome, Bone marrow blasts, Creatinine clearance or radioisotope GFR, Total bilirubin, SGOT (AST) or SGPT (ALT), Neutropenia, History of prolonged antifungal therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Ethnicity (NIH/OMB)"
      ],
      "remaining_candidate_features": [
        "Acute Myeloid Leukemia (AML) diagnosis",
        "Relapsed or refractory AML",
        "Secondary AML",
        "Myelodysplastic syndrome",
        "Bone marrow blasts",
        "Creatinine clearance or radioisotope GFR",
        "Total bilirubin",
        "SGOT (AST) or SGPT (ALT)",
        "Neutropenia",
        "History of prolonged antifungal therapy."
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), creatinine clearance or radioisotope glomerular filtration rate (GFR), serum creatinine, total bilirubin, serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT), diagnosis (de novo AML, relapsed AML, secondary AML, etc.), treatment plan, history of prolonged antifungal therapy, history of invasive fungal infection (IFI), history of echinocandin or fluconazole hypersensitivity.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "weight",
        "height",
        "body mass index (BMI)",
        "creatinine clearance or radioisotope glomerular filtration rate (GFR)",
        "serum creatinine",
        "total bilirubin",
        "serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate transaminase (SGPT)",
        "diagnosis (de novo AML, relapsed AML, secondary AML, etc.)",
        "treatment plan",
        "history of prolonged antifungal therapy",
        "history of invasive fungal infection (IFI)",
        "history of echinocandin or fluconazole hypersensitivity."
      ]
    }
  }
}